Skip to Navigation | Skip to Content
Post

UK becomes first to authorize Merck and Ridgeback Biotherapeutics’ antiviral molnupiravir to treat mild-to-moderate Covid-19
CNN Health

The UK Medicines and Healthcare Products Regulatory Agency said Thursday it had authorized Merck and Ridgeback Biotherapeutics’ oral antiviral, molnupiravir, to treat mild-to-moderate Covid-19 in adults at risk for severe illness.